Clotrimazole Vaginal Suppositories 150mg

Clotrimazole Vaginal Suppositories 150mg: What the Published Guidance Says

The obstetric emergency medicines and newborn-care antiseptics that sit on the WHO Model List — supplied with the labelling discipline these products demand.

Buyers usually settle three things before ordering Clotrimazole Vaginal Suppositories 150mg: the pharmacopoeial monograph, the pack configuration, and the documents the destination authority will ask for.

• Chlorhexidine for umbilical cord care is an EMLca medicine Section 22.7 of the Model List carries chlorhexidine 7.1% digluconate solution or gel — delivering 4% chlorhexidine — for umbilical cord care, added in 2013. MSF specifies a 3 g gel applied once daily for seven days to the tip, stump and base of the cord. WHO eEML — Chlorhexidine (umbilical cord care)
• Single-dose sachets are preferred, and the container matters MSF states the 3 g single-dose sachet or tube is preferred over the 20 g tube to minimise contamination from opened tubes, and warns against combining chlorhexidine with soap or other antiseptics such as povidone-iodine. MSF UniCat — Chlorhexidine 7.1%, umbilical cord gel
• Monitoring and the antidote Patellar reflex, blood pressure, heart and respiratory rate are checked every 15 minutes during the first hour, then hourly, with urine output checked hourly. If signs of overdose appear, magnesium sulfate is stopped and 1 g calcium gluconate given by slow intravenous injection as the antidote. MSF also notes magnesium sulfate should not be combined with nifedipine. MSF Essential Drugs — Magnesium sulfate injectable

These points are quoted because they shape how Clotrimazole Vaginal Suppositories 150mg is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.

How Clotrimazole Vaginal Suppositories 150mg Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Clotrimazole Vaginal Suppositories 150mg is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

• Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
• Testing for microbial limits and preservative efficacy (multi-dose presentations)
• Testing for heavy metals and elemental impurities
• Testing for packaging integrity and seal testing
• Testing for description and identification
• Testing for assay of the active substance

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Clotrimazole Vaginal Suppositories 150mg Is Packed, Labelled and Shipped

• Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
• Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
• Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Clotrimazole Vaginal Suppositories 150mg

Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.

• Batch manufacturing and packaging records released for inspection on request during supplier audits.
• Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
• CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
• Site Master File and GMP certificate for the manufacturing workshops.
• Method validation, stability protocol and the shelf-life justification for the marketed pack.

This page describes Clotrimazole Vaginal Suppositories 150mg as a product of the obstetric and newborn-care medicines named in the WHO Model List family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.